Oryzon Genomics S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ORYZF research report →
Price Chart
About the company
Oryzon Genomics S. A. is a clinical-stage biopharmaceutical company dedicated to advancing epigenetics-based therapies for individuals battling cancer and central nervous system (CNS) conditions.
- CEO
- Carlos Manuel Buesa Arjol
- IPO
- 2020
- Employees
- 46
- HQ
- Cornellà de Llobregat, CT, ES
Get TickerSpark's AI analysis on ORYZF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $253.86M
- P/E
- -84.94
- Fwd P/E
- 8.79
- PEG
- -1.46
- P/S
- 0.00
- P/B
- 1.72
- EV/EBITDA
- -30.40
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -2.23%
- ROIC
- -0.78%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $-133,855-101.9%
- Op Income
- $-6,416,519.5
- Net Income
- $-2,604,492+28.9%
- EPS
- $-0.04+38.2%
- OCF Growth
- +58.6%
- FCF Growth
- +82.0%
- 52W High
- $3.70
- 52W Low
- $3.10
- 50D MA
- $3.32
- 200D MA
- $3.45
- Beta
- 0.45
- RSI (14)
- 6
- Avg Volume
- 718
No earnings-call transcripts are available for ORYZF yet.
- Free Float
- 75.0%
- Shares Outstanding
- 81.96M
- Float Shares
- 61.45M
Our ORYZF coverage
Recent articles, reports, and earnings notes.
No research on ORYZF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ORYZF report →ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31st, 2026
globenewswire.com · May 14
ORYZON to Present Updated Positive Clinical Data for Iadademstat in Acute Myeloid Leukemia at EHA 2026
globenewswire.com · May 13
ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31st, 2025
globenewswire.com · Feb 27
ORYZON Expands Global Patent Protection for Iadademstat with Grant Decision in Japan Covering Combinations with PD-1/PD-L1 Inhibitors
globenewswire.com · Dec 22
ORYZON Announces the Voting Results of December 2025 Extraordinary General Shareholders' Meeting
globenewswire.com · Dec 15
ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2025
globenewswire.com · Nov 7
ORYZON Announces First‑Patient‑In (FPI) in RESTORE Phase Ib Trial of Iadademstat in Sickle Cell Disease
globenewswire.com · Nov 3
ORYZON to Participate in Upcoming Events in November
globenewswire.com · Oct 30
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.